Racial differences in the use of drug therapy for HIV disease in an urban community

Richard D Moore, David Stanton, Ramana Gopalan, Richard E Chaisson

Research output: Contribution to journalArticle

Abstract

Background. Guidelines for drug therapy in human immunodeficiency virus (HIV) disease are based primarily on the stage of the disease. To determine whether sociodemographic characteristics of patients influence drug therapy in practice, we analyzed the use of antiretroviral therapy and prophylactic therapy for Pneumocystis carinii pneumonia (PCP) in an urban population infected with HIV. Methods. All patients presenting for the first time to our HIV clinic from March 1990 through December 1992 were enrolled. Data on sociodemographic and clinical variables and on drug use were collected at the time of presentation and after six months. We asked whether patients with CD4+ cell counts of 500 or less per cubic millimeter were receiving antiretroviral therapy at the time of presentation, and whether patients with CD4+ cell counts of 200 or less per cubic millimeter were receiving PCP prophylaxis. Results. Among the 838 patients enrolled, 656 (79 percent) were blacks, 167 (20 percent) were non-Hispanic whites, and 15 (2 percent) were Asian or Hispanic or were not racially classified. There were no racial differences in the stage of HIV disease at the time of presentation. However, there were racial disparities in the receipt of antiretroviral therapy: 63 percent of eligible whites but only 48 percent of eligible blacks received such therapy (P = 0.003). PCP prophylaxis was received by 82 percent of eligible whites but only 58 percent of eligible blacks (P

Original languageEnglish (US)
Pages (from-to)763-768
Number of pages6
JournalNew England Journal of Medicine
Volume330
Issue number11
DOIs
StatePublished - Mar 17 1994

Fingerprint

Virus Diseases
HIV
Pneumocystis Pneumonia
Drug Therapy
CD4 Lymphocyte Count
Therapeutics
Urban Population
Hispanic Americans
Guidelines
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Racial differences in the use of drug therapy for HIV disease in an urban community. / Moore, Richard D; Stanton, David; Gopalan, Ramana; Chaisson, Richard E.

In: New England Journal of Medicine, Vol. 330, No. 11, 17.03.1994, p. 763-768.

Research output: Contribution to journalArticle

@article{779b05ed723b4291ad3e6ca76fc4bdc1,
title = "Racial differences in the use of drug therapy for HIV disease in an urban community",
abstract = "Background. Guidelines for drug therapy in human immunodeficiency virus (HIV) disease are based primarily on the stage of the disease. To determine whether sociodemographic characteristics of patients influence drug therapy in practice, we analyzed the use of antiretroviral therapy and prophylactic therapy for Pneumocystis carinii pneumonia (PCP) in an urban population infected with HIV. Methods. All patients presenting for the first time to our HIV clinic from March 1990 through December 1992 were enrolled. Data on sociodemographic and clinical variables and on drug use were collected at the time of presentation and after six months. We asked whether patients with CD4+ cell counts of 500 or less per cubic millimeter were receiving antiretroviral therapy at the time of presentation, and whether patients with CD4+ cell counts of 200 or less per cubic millimeter were receiving PCP prophylaxis. Results. Among the 838 patients enrolled, 656 (79 percent) were blacks, 167 (20 percent) were non-Hispanic whites, and 15 (2 percent) were Asian or Hispanic or were not racially classified. There were no racial differences in the stage of HIV disease at the time of presentation. However, there were racial disparities in the receipt of antiretroviral therapy: 63 percent of eligible whites but only 48 percent of eligible blacks received such therapy (P = 0.003). PCP prophylaxis was received by 82 percent of eligible whites but only 58 percent of eligible blacks (P",
author = "Moore, {Richard D} and David Stanton and Ramana Gopalan and Chaisson, {Richard E}",
year = "1994",
month = "3",
day = "17",
doi = "10.1056/NEJM199403173301107",
language = "English (US)",
volume = "330",
pages = "763--768",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "11",

}

TY - JOUR

T1 - Racial differences in the use of drug therapy for HIV disease in an urban community

AU - Moore, Richard D

AU - Stanton, David

AU - Gopalan, Ramana

AU - Chaisson, Richard E

PY - 1994/3/17

Y1 - 1994/3/17

N2 - Background. Guidelines for drug therapy in human immunodeficiency virus (HIV) disease are based primarily on the stage of the disease. To determine whether sociodemographic characteristics of patients influence drug therapy in practice, we analyzed the use of antiretroviral therapy and prophylactic therapy for Pneumocystis carinii pneumonia (PCP) in an urban population infected with HIV. Methods. All patients presenting for the first time to our HIV clinic from March 1990 through December 1992 were enrolled. Data on sociodemographic and clinical variables and on drug use were collected at the time of presentation and after six months. We asked whether patients with CD4+ cell counts of 500 or less per cubic millimeter were receiving antiretroviral therapy at the time of presentation, and whether patients with CD4+ cell counts of 200 or less per cubic millimeter were receiving PCP prophylaxis. Results. Among the 838 patients enrolled, 656 (79 percent) were blacks, 167 (20 percent) were non-Hispanic whites, and 15 (2 percent) were Asian or Hispanic or were not racially classified. There were no racial differences in the stage of HIV disease at the time of presentation. However, there were racial disparities in the receipt of antiretroviral therapy: 63 percent of eligible whites but only 48 percent of eligible blacks received such therapy (P = 0.003). PCP prophylaxis was received by 82 percent of eligible whites but only 58 percent of eligible blacks (P

AB - Background. Guidelines for drug therapy in human immunodeficiency virus (HIV) disease are based primarily on the stage of the disease. To determine whether sociodemographic characteristics of patients influence drug therapy in practice, we analyzed the use of antiretroviral therapy and prophylactic therapy for Pneumocystis carinii pneumonia (PCP) in an urban population infected with HIV. Methods. All patients presenting for the first time to our HIV clinic from March 1990 through December 1992 were enrolled. Data on sociodemographic and clinical variables and on drug use were collected at the time of presentation and after six months. We asked whether patients with CD4+ cell counts of 500 or less per cubic millimeter were receiving antiretroviral therapy at the time of presentation, and whether patients with CD4+ cell counts of 200 or less per cubic millimeter were receiving PCP prophylaxis. Results. Among the 838 patients enrolled, 656 (79 percent) were blacks, 167 (20 percent) were non-Hispanic whites, and 15 (2 percent) were Asian or Hispanic or were not racially classified. There were no racial differences in the stage of HIV disease at the time of presentation. However, there were racial disparities in the receipt of antiretroviral therapy: 63 percent of eligible whites but only 48 percent of eligible blacks received such therapy (P = 0.003). PCP prophylaxis was received by 82 percent of eligible whites but only 58 percent of eligible blacks (P

UR - http://www.scopus.com/inward/record.url?scp=0028202480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028202480&partnerID=8YFLogxK

U2 - 10.1056/NEJM199403173301107

DO - 10.1056/NEJM199403173301107

M3 - Article

C2 - 8107743

AN - SCOPUS:0028202480

VL - 330

SP - 763

EP - 768

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 11

ER -